Lexaria Bioscience (LEXX) Free Cash Flow (2010 - 2026)

Lexaria Bioscience has disclosed Free Cash Flow across 17 years of filings, most recently posting -$2.2 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$2.2 million, down 47.19% year-over-year; the trailing twelve-month figure through Feb 2026 was -$9.4 million (down 26.39% YoY), and the FY2025 annual result was -$10.5 million, down 109.42% from the prior year.
• Free Cash Flow came in at -$2.2 million for Q1 2026 at Lexaria Bioscience, down from -$984098.0 in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$619614.0 in Q1 2024 to a low of -$3.6 million in Q2 2025.
• The 5-year median for Free Cash Flow is -$1.3 million (2022), against an average of -$1.7 million.
• Peak annual rise in Free Cash Flow reached 64.22% in 2025, while the deepest fall reached 183.08% in 2025.
• Lexaria Bioscience's Free Cash Flow stood at -$1.3 million in 2022, then climbed by 6.65% to -$1.2 million in 2023, then tumbled by 132.78% to -$2.8 million in 2024, then surged by 64.22% to -$984098.0 in 2025, then sank by 124.03% to -$2.2 million in 2026.
• The last three Free Cash Flow figures came in at -$2.2 million (Q1 2026), -$984098.0 (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.